BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18216299)

  • 21. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
    Bianchi G; Kumar S
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
    Weiss BM; Wong SW; Comenzo RL
    Blood; 2016 May; 127(19):2275-80. PubMed ID: 26907632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
    Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
    Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis.
    Abraham RS; Ballman KV; Dispenzieri A; Grill DE; Manske MK; Price-Troska TL; Paz NG; Gertz MA; Fonseca R
    Blood; 2005 Jan; 105(2):794-803. PubMed ID: 15388584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
    Veri MC; Burke S; Huang L; Li H; Gorlatov S; Tuaillon N; Rainey GJ; Ciccarone V; Zhang T; Shah K; Jin L; Ning L; Minor T; Moore PA; Koenig S; Johnson S; Bonvini E
    Arthritis Rheum; 2010 Jul; 62(7):1933-43. PubMed ID: 20506263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
    Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
    Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
    Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
    Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.
    Paiva B; Martinez-Lopez J; Corchete LA; Sanchez-Vega B; Rapado I; Puig N; Barrio S; Sanchez ML; Alignani D; Lasa M; García de Coca A; Pardal E; Oriol A; Garcia ME; Escalante F; González-López TJ; Palomera L; Alonso J; Prosper F; Orfao A; Vidriales MB; Mateos MV; Lahuerta JJ; Gutierrez NC; San Miguel JF
    Blood; 2016 Jun; 127(24):3035-9. PubMed ID: 27069257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1.
    Carbone A; Gloghini A; Gattei V; Degan M; Improta S; Aldinucci D; Canzonieri V; Perin T; Volpe R; Gaidano G; Zagonel V; Pinto A
    Blood; 1997 May; 89(10):3787-94. PubMed ID: 9160685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.
    Granzow M; Hegenbart U; Hinderhofer K; Hose D; Seckinger A; Bochtler T; Hemminki K; Goldschmidt H; Schönland SO; Jauch A
    Haematologica; 2017 Jul; 102(7):1281-1290. PubMed ID: 28341732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.
    Hu Y; Wang M; Chen Y; Chen X; Fang F; Liu S; Zhang Y; Wu X; Zhu P
    Chin Med J (Engl); 2014; 127(15):2765-70. PubMed ID: 25146610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
    Williams EL; Tutt AL; Beers SA; French RR; Chan CH; Cox KL; Roghanian A; Penfold CA; Butts CL; Boross P; Verbeek JS; Cragg MS; Glennie MJ
    J Immunol; 2013 Oct; 191(8):4130-40. PubMed ID: 24026082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of nodular cutaneous amyloidosis. Amyloid production by infiltrating plasma cells.
    Horiguchi Y; Takahashi C; Imamura S
    Am J Dermatopathol; 1993 Feb; 15(1):59-63. PubMed ID: 8434733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extranodal marginal zone B cell lymphomas of the uvea: an analysis of 13 cases.
    Coupland SE; Foss HD; Hidayat AA; Cockerham GC; Hummel M; Stein H
    J Pathol; 2002 Jul; 197(3):333-40. PubMed ID: 12115879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
    Parrondo RD; Majeed U; Sher T
    Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.
    Comenzo RL; Zhang Y; Martinez C; Osman K; Herrera GA
    Blood; 2001 Aug; 98(3):714-20. PubMed ID: 11468171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association.
    Cohen AD; Zhou P; Xiao Q; Fleisher M; Kalakonda N; Akhurst T; Chitale DA; Moscowitz C; Dhodapkar MV; Teruya-Feldstein J; Filippa D; Comenzo RL
    Br J Haematol; 2004 Feb; 124(3):309-14. PubMed ID: 14717777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis.
    Yoshida T; Matsuda M; Katoh N; Tazawa K; Shimojima Y; Gono T; Ishii W; Nakazawa Y; Sakashita K; Koike K; Yamada T; Ikeda S
    Intern Med; 2008; 47(20):1783-90. PubMed ID: 18854629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and management of systemic light chain AL amyloidosis.
    Bhutani D; Lentzsch S
    Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
    Muchtar E; Dispenzieri A; Jevremovic D; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Warsame R; Kourelis TV; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
    Amyloid; 2020 Mar; 27(1):13-16. PubMed ID: 31544536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.